Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MVIR.ST
SELLREMOVEMedivir AB (publ) · Healthcare · Sweden · $118M · Avg Vol: $472K/d
Medivir is a clinical-stage oncology biotech. It is pre-revenue, highly speculative, and lacks any of the structural moats or financial strength required by our Buffett and Terry Smith lenses.
COMPANY DESCRIPTION
Medivir AB is a Swedish clinical-stage pharmaceutical company dedicated to developing innovative, targeted therapies for hard-to-treat cancers, with a primary focus on orphan oncology indications. The company's lead clinical candidate, fostroxacitabine bralpamide (fostrox), is being evaluated in combination therapies for primary liver cancer (HCC) and has received orphan drug designation from both the FDA and EMA. Medivir leverages a lean, virtual development model, partnering with global pharmaceutical companies to advance its pipeline while minimizing capital expenditure.
FINANCIAL SUMMARY
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 478,494 | 828,680 | 378,192 | 923,337 | 24.5% |
| EPS | -0.17 | -0.16 | -0.12 | -0.07 | — |
| Shares | 68M | 105M | 115M | 451M | +563.1% |
| Debt | 2M | 1M | 1M | 910,636 | -18.5% |
| Equity | 21M | 24M | 13M | 17M | -7.0% |
| Op CF | -11M | -6M | -13M | -8M | — |
| Inv CF | -41,467 | -28,332 | 0 | 0 | — |
| Fin CF | -166,626 | 12M | 2M | 14M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MVIR.ST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MVIR.ST | Medivir AB (publ)(you) | $118M | 27 | SELL |
| IBT-B.ST | Infant Bacterial Therapeutics AB (publ) | $82M | 18 | STRONG SELL |
| FLERIE.ST | Flerie AB (publ) | $242M | 23 | SELL |
| BINV.ST | BioInvent International AB (publ) | $239M | 20 | STRONG SELL |
| SYNACT.ST | SynAct Pharma AB | $102M | 7 | STRONG SELL |
| XSPRAY.ST | Xspray Pharma AB (publ) | $126M | 5 | STRONG SELL |
| EGTX.ST | Egetis Therapeutics AB (publ) | $297M | 22 | SELL |
| GENO.ST | Genovis AB (publ.) | $144M | 48 | HOLD |
| HNSA.ST | Hansa Biopharma AB (publ) | $365M | 30 | SELL |
| ONCO.ST | Oncopeptides AB (publ) | $76M | 6 | STRONG SELL |
Peer medians: ROE 5.1% · P/E 37.9x · Gross margin 62.3%